T‐CELL LYMPHOMA IN THE ELDERLY PATIENTS. WHO IS YOUNG, OLD, AND ELDERLY?

Introduction: Ageing of lymphoma population becomes the medical problem with growing proportion of patients > 60 years. Moreover, the term “elderly” is vague comprising people old between 61 to more than 100 years. We decided to analyze prognosis of the T-cell lymphoma patients >60yrs and different age subgroups within this cohort. Methods: We used CLSG (Czech Lymphoma Study Group) database (Govtrial NT 03199066) for the retrospective analysis, where the cohorts of patients were compared according to their age at diagnosis (<60 yrs, 60-<65, 65-<70, 70-<75, and ≥ 75 yrs), in terms of baseline parameters, treatment and survival. Results: In total, 906 patients with new systemic T-cell lymphoma diagnosed 1999-2015 were identified, including 471 (52%) pts >60 years, 140 (15%) pts between 60 and <65yrs, 111 (12%) pts between 65-<70yrs, 101 (11%) pts between 70-<75yrs and 119 (13%) pts ≥75 yrs. With the age increases proportion of ECOG 3-4 (9.6% vs. 11.7% vs. 12.7% vs. 15% vs. 21.8%), and especially in cohort ≥75yrs decreases frequency of B-symptoms (44.5% vs. 55.2% vs. 51.4% vs. 54.5% vs. 36.3%). Proportion of sex, stage, bone marrow infiltration, bulky disease, and extranodal involvement were similar across age-groups. Systemic chemotherapy was administered in 83.4% vs. 87.1% vs. 84.7% vs. 86.1% and 63% pts, including CHOP like therapy in 36% vs. 55% vs. 47% vs. 57% vs. 29%, CHOEP was given in 18% vs. 13% vs. 13% vs. 2% vs. 2%, and more intensive regimens were administered in 18% vs. 10% vs. 1% vs. 0% vs. 0%. In the 1st-line, auto-SCT was performed in 16.3% vs. 13.6% vs. 1.8% vs. 0% vs. 0% pts, but alo-transplants in 1.4% pts <60yrs only. Overall survival (OS) differs significantly among cohorts with median 9.8 vs. 2.2 vs. 2.2 vs. 2.6 vs. 1.3 yrs (Table; p<0.001). Further, we analyzed survival according to IPI in three cohorts (<60yrs vs. 60-<75yrs vs. ≥75 yrs). Survival differences remained significant in the IPI low risk patients with median not reached for group <60yrs, 11.4yrs (95% CI; 5.6-17.3) for age 60-<75yrs and 3.4yrs (95% CI; 0.6-6.3) for patients ≥75yrs (p<0.001). For higher IPI groups, there were no significant differences in OS and PFS among age-cohorts. Conclusions: There is evident that elderly T-cell lymphoma patients (>60yrs) represent heterogenous population, where we can recognise the patients aged 60- <75yrs who share similar clinical characteristics and similar outcomes and patients ≥75 yrs with significantly worse prognosis. Interestingly, the cohort of patients 60- <75 yrs has similar survival regardless difference in the therapy intensity. Keywords: elderly; peripheral T-cell lymphomas (PTCL); prognostic indices. 434 – WITHDRAWN